Cordis brings two new catheters to U.S. market

Cordis, a subsidiary of Johnson & Johnson, has introduced its Fire Star Rx PTCA Dilatation Catheter and its Dura Star Rx PTCA Dilatation Catheter into the U.S. market.

The U.S. FDA approved the commercialization of these products in late August.

According to the Miami Lakes, Fla.-based Cordis, the Fire Star balloon features a low pre-dilatation profile and the Dura Star balloon is suited for use with both drug-eluting and bare metal balloon-expandable stents.

Both balloons will be offered to catheterization laboratories and interventional cardiologists on Oct. 15.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup